X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Local Impact: Improving diabetes care for children in Medicaid

By Samantha Dougherty  |    October 13, 2015
Earlier this fall we looked at how Medicaid beneficiaries adhering to their prescription drug regimens could result in a decline in expensive hospitalizations and emergency room visits, and...   Read More

Medicare Monday: Adherence in Medicare and Medicaid saves money

By Allyson Funk  |    September 14, 2015
If you’ve been following along with Medicare Monday, you’ve undoubtedly heard us talk about how adherence to prescription medicines helps save money in Medicare. Due to a growing body of evidence,...   Read More

Study: Better use of prescription drugs by Medicaid beneficiaries can yield significant savings

By Samantha Dougherty  |    September 9, 2015
If Medicaid beneficiaries adhered to their prescription drug regimens, they could significantly reduce U.S. medical costs, by reducing expensive hospitalizations and emergency room visits. A new...   Read More

GAO: Prescription Drugs Are Just 2% of Medicaid Spending

By Allyson Funk  |    August 5, 2015
Last week, the Government Accountability Office (GAO) released a detailed look at Medicaid and key issues facing the program. Despite rhetoric about the cost of prescription medicines in Medicaid,...   Read More

New Chart Pack: Biopharmaceuticals in Government Programs

By Allyson Funk  |    July 16, 2015
Today, PhRMA released a new resource on biopharmaceuticals in government programs. This new chart pack features key facts about prescription medicines in four major government programs – Medicare,...   Read More

Who Benefits from the 340B Drug Discount Program?

By Allyson Funk  |    June 10, 2015
The 340B program was created by Congress in 1992 to help vulnerable or uninsured patients gain access to needed prescription medicines, by requiring pharmaceutical manufacturers to provide steep...   Read More

340B Spotlight: A Look at 340B Purchases

By Karyn Schwartz  |    June 3, 2015
If you are familiar with the 340B program, you have probably heard the oft-cited assertion that 340B only represents 2% of pharmaceutical sales.[1] But just because a statistic is widely repeated,...   Read More

Week in Review: The Latest from PhRMA

By Mollymae Metheny  |    April 10, 2015
The reality of prescription drug spending in Medicaid, more than 240 Medicines in Development to treat blood cancers, PPA celebrates its 10th anniversary, look at a patient with rheumatoid...   Read More

The Reality of Prescription Drug Spending in Medicaid

By Robert Zirkelbach  |    April 9, 2015
Recent rhetoric on spending in state Medicaid programs often overstates the cost impact of prescription medicines and ignores the competitive biopharmaceutical market that exists in the U.S.,...   Read More

340B Paradox: As the Uninsured Rate Drops, 340B Program Continues to Grow

By Karyn Schwartz  |    April 2, 2015
Recent studies show the Affordable Care Act (ACA) has reduced the uninsured rate and lowered the amount of uncompensated care that hospitals provide. Paradoxically, these welcome trends are also...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

Subscribe to Email Updates